Evidenzbasierte Therapie degenerativer Gelenkerkrankungen: Teil 2: Medikamentöse Therapien

T. Rosemann

doi:10.1055/s-2007-1004534

ZFA - Zeitschrift für Allgemeinmedizin, Inhaltsverzeichnis

ZFA (Stuttgart) 2008; 84(1): 28-35
DOI: 10.1055/s-2007-1004534

Übersicht

Evidenzbasierte Therapie degenerativer Gelenkerkrankungen: Teil 2: Medikamentöse Therapien

Evidence Based Therapy of Degenerative Joint Diseases - Medical Treatment OptionsT. Rosemann¹

¹Abteilung Allgemeinmedizin und Versorgungsforschung, Universitätsklinikum Heidelberg

Abstract

Zusammenfassung

Medikament der ersten Wahl in der Therapie der Arthrose ist Paracetamol, da es das beste Nutzen/Risikoprofil besitzt. Nicht steroidale Antirheumatika (NSAR) sind etwas stärker analgetisch wirksam und besitzen zudem eine antiphlogistische Komponente, ihr Einsatz sollte jedoch zeitlich immer eng begrenzt sein und im Wesentlichen der akut-entzündlichen Arthritis vorbehalten bleiben. Mittel der Wahl ist hierbei Diclofenac. Gemäß der derzeitigen Datenlage sollte bei Patienten mit einem erhöhten Gastrointestinalen Risiko eine Kombinationstherapie aus einem traditionellen NSAR und einem Protonenpumpenhemmer erfolgen. Alternativ können Coxibe zum Einsatz kommen, sofern keine Kontraindikationen vorliegen. Coxibe und traditionelle NSAR - außer dem ASS und eventuell dem Naproxen - sind mit einem erhöhten kardiovaskulären Risiko assoziiert. Daher sollten diese Substanzen bei Patienten mit kardiovaskulären Risikofaktoren nicht oder nur nach strengster Indikationsstellung zum Einsatz kommen. Opiode haben bei kritischer Indikationsstellung ihre berechtige Stellung in der Arthrosetherapie. Sie sollten Bestandteil eines Schmerzregimes sein, das ein Schmerztagebuch und regelmäßige Reevaluationen beinhaltet. Wichtig ist, dem Patienten das Ziel der medikamentösen Therapie, die Aufrechterhaltung der für die Gelenkfunktion bedeutsamen körperlichen Aktivität deutlich zu machen. Aufgrund der häufigen Selbstmedikation und der Inanspruchnahme von alternativmedizinischen Heilverfahren sollten auch diese Elemente im Therapiekonzept berücksichtigt werden. Ebenso wie eine begleitende Depression, die wie bei vielen chronischen Erkrankungen auch unter Arthrosepatienten gehäuft auftritt.

Abstract

First-choice medication in the therapy of osteoarthritis is paracetamol since it offers the best benefit/risk profile. Non-steroidal anti-inflammatory drugs (NSAIDs) are slightly more effective analgesics and offer an additional antipyretic component. Nevertheless, their usage should always be strictly limited temporally and reserved to the treatment of acute inflammatory osteoarthritis. In that case, first-choice medication is diclofenac. Regarding current study results, patients with an increased gastrointestinal risk should be treated with a combination therapy composed of a traditional NSAID and a proton pump inhibitor. Alternatively, COX-2 inhibitors might be used if there are no contraindications. COX-2 inhibitors and traditional NSAIDs - with the exception of aspirin and possibly naproxen - are associated with an increased cardiovascular risk. Therefore, patients with cardiovascular risk factors should not be treated with those substances or only after a rigorous examination of indication. A critical indication qualifies opioids to treat osteoarthritis. They should be part of a pain regimen which contains a pain diary and regular evaluations. It is important for the patient to illustrate the aim of the drug therapy, the maintenance of physical activity which is vital for joint functioning. Since patients often use over-the-counter medication and alternative medicine, these elements should also be considered within the therapeutic concept. As well as a comorbid depression which prevalence is - as it is in many other chronic diseases - increased among patients with osteoarthritis.

Schlüsselwörter

Arthrose - nicht steroidale Antirheumatika (NSAR) - Schmerztherapie

Key words

Osteoarthritis - non-steroidal anti-inflammatory drug (NSAID) - pain treatment

Volltext

Referenzen

Literatur

1 Statistisches Bundesamt .Statistisches Jahrbuch 2000 für die Bundesrepublik Deutschland. Stuttgart: Metzler Poeschel 2000
2 Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1987; 30 914-918
3 Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol Suppl. 1991; 28 6-10
4 Towheed TE, Maxwell L, Anastassiades TP. et al . Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005; ((2)) CD002946
5 Reichenbach S, Sterchi R, Scherer M. et al . Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007; 146 580-590
6 Ayral X. Injections in the treatment of osteoarthritis. Best Pract Res Clin Rheumatol. 2001; 15 609-626
7 Gerwin N, Hops C, Lucke A. Intraarticular drug delivery in osteoarthritis. Adv Drug Deliv Rev. 2006; 58 226-242
8 Goldberg VM, Buckwalter JA. Hyaluronans in the treatment of osteoarthritis of the knee: evidence for disease-modifying activity. Osteoarthritis Cartilage. 2005; 13 216-224
9 Ong CK, Lirk P, Tan CH, Seymour RA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007; 5 19-34
10 Jordan KM, Arden NK, Doherty M. et al . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62 1145-1155
11 Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis. 2004; 63 901-907
12 Rosemann T, Wensing M, Joest K, Backenstrass M, Mahler C, Szecsenyi J. Problems and needs for improving primary care of osteoarthritis patients: the views of patients, general practitioners and practice nurses. BMC Musculoskelet Disord. 2006; 7 48
13 Larson AM, Polson J, Fontana RJ. et al . Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005; 42 1364-1372
14 North of England Evidence Based Guideline Development Project . , Evidence Based Clinical Practice Guideline. Non-steroidal antiinflammatory drugs (NSAIDs) versus basic analgesia in the treatment of pain believed to be due to degenerative arthritis. University of Newcastle upon Tyne, editor. Report No. 86. 1998. Newcastle upon Tyne, Centre for Health Services Research
15 Towheed TE, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev. 2006; 2 ((2)) CD000517
16 Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev. 2000; 1 ((2)) CD000142
17 Jordan KM, Arden NK, Doherty M. et al . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62 1145-1155
18 Zhang W, Doherty M, Arden N. et al . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005; 64 669-681
19 Towheed TE, Hochberg MC, Shea BJ, Wells G. WITHDRAWN: Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. Cochrane Database Syst Rev. 2006; 1 ((1)) CD000517
20 European Medicines Evaluation Agency (EMEA) . , Post-authorisation Evaluation of Medicines for Human Use Public assessment report for medicinal products containing non-selective non steroidal antiinflammatory drugs (NSAIDs). Procedure No. EMEA/H/A-5.3/800 under Article 5(3) of Regulation (EC) No 726/2004. EMEA/CHMP/442130/2006. 2006. London, 7. November
21 European Medicines Evaluation Agency (EMEA) . , Questions and Answers on the review of piroxicam: http://www.emea.europa.eu/pdfs/human/press/pr/piroxicam_26457807en.pdf 2007; , Internetquelle zuletzt geprüft: 5. Juli, EMEA 2007
22 Bensen WG, Fiechtner JJ, McMillen JI. et al . Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999; 74 1095-1105
23 Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000; 59 957-980
24 McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol. 2001; 30 11-18
25 Silverstein FE, Faich G, Goldstein JL. et al . Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284 1247-1255
26 Curtis SP, Bockow B, Fisher C. et al . Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489]. BMC Musculoskelet Disord. 2005; 6 58
27 Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006; 25 S22-S29
28 Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991; 115 787-796
29 Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114 257-263
30 Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000; 85 169-182
31 AkdAe . Kreuzschmerzen - Therapieempfehlungen der Arzneimittelkommission. Arzneiverordnung in der Praxis. 2007; 34 , (Sonderheft, 3. Aufl.)
32 Emery P, Zeidler H, Kvien TK. et al . Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999; 354 2106-2111
33 Simon LS, Weaver AL, Graham DY. et al . Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999; 282 1921-1928
34 Hunt RH, Harper S, Watson DJ. et al . The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98 1725-1733
35 Emery P, Zeidler H, Kvien TK. et al . Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999; 354 2106-2111
36 Cannon CP, Curtis SP, FitzGerald GA. et al . Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368 1771-1781
37 Schnitzer TJ, Burmester GR, Mysler E. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004; 364 665-674
38 FDA . , Medical Officer's Gastroenterology Advisory Committee Briefing Document: Division of Anti-Inflammatory, Analgesic and Ophthalmologic Drug Products: HFD-550. Name of drug: Celecoxib (Celebrex™): http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_05_gi.doc 2007; , zuletzt geprüft: 21. Februar, NDA 20-998/S-009 (Reviewer: Lawrence Goldkind M. D.); 07. Februar 2000
39 European Medicines Evaluation Agency (EMEA) . , Wissenschaftliche Schlussfolgerungen der EMEA und Begründung für die Änderung der Zusammenfassung(en) der Merkmale der Arzneimittel. EMEA/CPMP/1749/04. Anhang II: http://www.emea.eu.int/pdfs/human/referral/rofecoxib/DE%20Rofecoxib.pdf 2007; , Internetquelle zuletzt geprüft: 21. Februar, EMEA 2004
40 FDA . , Arthritis & Drug Safety and Risk Management. Advisory Committee Briefing Package. February 16, 17, and 18, 2005: ARCOXIA (etoricoxib) NDA 21-389 (pending), Safety Review of Safety and GI (Dr. Schiffenbauer): http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090b1-01.htm 2007; , Zuletzt geprüft: 21. Februar
41 Farkouh ME, Kirshner H, Harrington RA. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364 675-684
42 Schnitzer TJ, Burmester GR, Mysler E. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004; 364 665-674
43 Hart L. Lumiracoxib reduced ulcer complications compared with ibuprofen and naproxen in osteoarthritis and did not increase cardiovascular outcomes. ACP J Club. 2005; 142 46-47
44 Graham DY, Agrawal NM, Campbell DR. et al . Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002; 162 169-175
45 Hawkey CJ, Karrasch JA, Szczepanski L. et al . Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998; 338 727-734
46 Rostom A, Dube C, Wells G. et al . Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2004; ((4)) CD002296
47 Yeomans ND, Swannell AJ, Walan A. Direct comparison of omeprazol and misoprostol as maintenance for NSAID-associated gastroduodenal ulcers, erosions and symptoms. Rheumatol Eur. 1996; 25 ((Suppl)) 80
48 Yeomans ND, Swannell AJ, Wilson RR, Naesdal J, Hawkey CJ. Maintenance treatment for NSAID-associated ulcers and erosions with omeprazole, misoprostol and ranitidine: the ASTRONAUT and OMNIUM trials. Am J Gastroenterol. 1997; 92 1628
49 Silverstein FE, Graham DY, Senior JR. et al . Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995; 123 241-249
50 Stupnicki T, Dietrich K, Gonzalez-Carro P. et al . Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion. 2003; 68 198-208
51 Pallay RM, Seger W, Adler JL. et al . Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol. 2004; 33 257-266
52 See Y, Ng SC, Tho KS, Teo SK. Are antacids necessary as routine prescriptives with non-steroidal anti-inflammatory drugs?. Ann Acad Med Singapore. 1998; 27 219-222
53 Sievert W, Stern AI, Lambert JR, Peacock T. Low-dose antacids and nonsteroidal anti-inflammatory drug-induced gastropathy in humans. J Clin Gastroenterol. 1991; 13 145-148
54 Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 1996; 156 1530-1536
55 Lai KC, Chu KM, Hui WM. et al . Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005; 118 1271-1278
56 Spiegel BM, Farid M, Dulai GS, Gralnek IM, Kanwal F. Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis. Am J Med. 2006; 119 448-436
57 Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK. et al . Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347 2104-2110
58 Chan FK, Hung LC, Suen BY. et al . Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology. 2004; 127 1038-1043
59 Lai KC, Chu KM, Hui WM. et al . Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005; 118 1271-1278
60 Herdegen T, Fauler J. Zur Arzneimittelsicherheit von NSAR und COX-2-Hemmern. Arzneimitteltherapie. 2006; 24 84-89
61 Herxheimer A. Many NSAID users who bleed don't know when to stop. BMJ. 1998; 316 492
62 Merck without Vioxx . FDA issues public health advisory. FDA Consum. 2004; 38 ((Issue 6))
63 Cannon CP, Curtis SP, FitzGerald GA. et al . Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006; 368 1771-1781
64 FDA . , Arthritis & Drug Safety and Risk Management. Advisory Committee Briefing Package. February 16, 17, and 18, 2005: ARCOXIA (etoricoxib) NDA 21-389 (pending), Safety Review of Safety and GI (Dr. Schiffenbauer): http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090b1-01.htm 2007; , zuletzt geprüft: 21. Februar
65 Farkouh ME, Kirshner H, Harrington RA. et al . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004; 364 675-684
66 Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330 1366
67 McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296 1633-1644
68 Bombardier C, Laine L, Reicin A. et al . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343 1520-1528 , , 2
69 Helin-Salmivaara A, Virtanen A, Vesalainen R. et al . NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006; 27 1657-1663
70 Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005; 330 1366
71 Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy. 2005; 25 503-510
72 Chan AT, Manson JE, Albert CM. et al . Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006; 113 1578-1587
73 Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332 1302-1308
74 Hermann M, Ruschitzka F. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs. Ann Med. 2007; 39 18-27
75 Hessen KV. Hoch dosiertes Ibuprofen kann Wirkung von niedrig dosiertem ASS abschwächen. KV Hessen aktuell. 2007; ((1))
76 Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin Rheumatol. 2006; 25 22-29
77 Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003; 52 600-608
78 Klinische Nephrologie . , München, Urban & Fischer 2000
79 Brune K, Lemmer B. Is homeopathic medicine equivalent to diclo-fenac? An opinion statement against misleading. Orthopäde. 2000; 29 271-272
80 McQuay HJ, Moore RA. Comparing analgesic efficacy of non-steroidal anti-inflammatory drugs given by different routes in acute and chronic pain. In: McQuay HJ, Moore RA (Eds) An evidence-based resource for pain relief. Oxford, New York, Tokyo: Oxford University Press 1998: 94-101
81 Arzneimittelkommission der deutschen Ärzteschaft . Anaphylaktische Schockreaktionen nach parenteraler Gabe von Diclofenac. Dtsch Arztebl. 1995; 92 A71
82 Jordan KM, Arden NK, Doherty M. et al . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62 1145-1155
83 Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004; 329 324-330
84 Towheed TE. Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2006; 33 567-573
85 Felson DT, Lawrence RC, Hochberg MC. et al . Osteoarthritis: new insights. Part 2: treatment approaches. Ann Intern Med. 2000; 133 72-737
86 Jordan KM, Arden NK, Doherty M. et al . EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003; 62 1145-1155
87 Zhang W, Doherty M, Arden N. et al . EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005; 64 669-681
88 Chou R, Clark E, Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage. 2003; 26 1026-1048
89 Staats PS, Markowitz J, Schein J. Incidence of constipation associated with long-acting opioid therapy: a comparative study. South Med J. 2004; 97 129-134
90 AkdAe . , Empfehlungen zur Therapie von Tumorschmerzen. Arzneiverordnung in der Praxis 2007; 34 (Sonderheft 1, 3. Aufl.)
91 Sorgatz, H, Hege-Scheuing G, Kopf A. et al . Langzeitanwendung von Opioiden bei nichttumorbedingten Schmerzen. Dtsch Ärztebl. 2002; 99 2180
92 Strumpf M, Willweber-Strumpf A. Opioid-Therapie bei Nicht-Tumorschmerzen. MMW-Forschr Med. 2003; 145 270

Korrespondenzadresse

PD Dr. med. T. Rosemann

Abteilung Allgemeinmedizin und Versorgungsforschung Universitätsklinikum

Heidelberg

Vosstr. 2

69115 Heidelberg

eMail: thomas.rosemann@med.uni-heidelberg.de